Core Insights - MiMedx Group, Inc. has launched CHORIOFIX™, an advanced wound care product that expands its portfolio of placental allografts [1][2] Product Details - CHORIOFIX is developed from a deep understanding of the chorion layer, featuring two chorion layers with an intact intermediate layer, making it the thickest product to date [2] - The product's structure enhances handling during positioning and suturing, and its dual-sided configuration eliminates the need for orientation during application [2] - CHORIOFIX is designed for use in acute and chronic wounds, providing a protective barrier [3] Clinical Evaluation - Early evaluations by healthcare professionals indicate positive handling characteristics and effective wound closure, particularly for large deficits and deep, tunneling wounds [2] - CHORIOFIX has been added to the CAMPAIGN trial, a randomized controlled trial aimed at evaluating its performance against standard care in treating non-healing diabetic foot ulcers [2] Company Overview - MiMedx is a leader in advanced wound care, focusing on innovative solutions to help manage chronic and hard-to-heal wounds [4] - The company aims to be the leading global provider of healing solutions through relentless innovation [4]